Variables | Validation cohort |  | Training cohort | χ2/t value | P |
---|---|---|---|---|---|
Mean ± SD/N (%) |  | Mean ± SD/N (%) | |||
Gender(male/female) | 39(60.9%)/25(39.1%) | Â | 54(56.3%)/42(43.8%) | 0.347 | 0.556 |
Age,years | 66.2 ± 8.9 |  | 62.1 ± 10.6 | 2.488 | 0.014 |
Bismuth-Corlette classification(I/II/IIIA/IIIB/IV) | 8(12.5%)/6(9.4%)/15(23.4%)/19(29.7%)/16(25.0%) | Â | 8(8.3%)/16(16.7%)/16(16.7%)/23(24.0%)/33(34.4%) | 4.642 | 0.326 |
CEA level, ng/ml(≤ 5/>5) | 47(73.4%)/17(26.6%) |  | 69(71.9%)/27(28.1%) | 0.047 | 0.828 |
CA19-9 level, U/mL(≤ 559.8/>559.8) | 47(73.4%)/17(26.6%) |  | 61(63.5%)/35(36.5%) | 1.714 | 0.190 |
DB level, umol/l (≤ 8/>8) | 9(14.1%)/55(85.9%) |  | 24(25.0%)/72(75.0%) | 2.806 | 0.094 |
TB level,umol/l (≤ 34/>34) | 11(17.2%)/53(82.8%) |  | 23/(24.0%)/73(76.0%) | 1.052 | 0.305 |
Tumor diameter, cm | 2.9 ± 1.3 |  | 3.3 ± 1.6 | 1.707 | 0.090 |
Biliary calculi(no/yes) | 48(75.0%)/16(25.0%) | Â | 77(80.2%)/19(19.8%) | 0.610 | 0.435 |
Pathological differentiation(poor/moderate/well) | 27(42.2%)/32(50.0%)/5(7.8%) | Â | 36(37.5%)/52(54.2%)/8(8.3%) | 0.354 | 0.838 |
cN stage(0/N1/N2) | 37(57.8%)/22(34.4%)/5(7.8%) | Â | 46(47.9%)/40(41.7%)/10(10.4%) | 1.530 | 0.465 |
Number of lymph node dissection(< 7/≥7) | 28(43.8%)/36(56.3%) |  | 32(33.3%)/64(66.7%) | 1.778 | 0.182 |
AJCC T stage (T1-2 / T3-4) | 29(45.3%)/35(54.7%) | Â | 32(33.3%)/64(66.7%) | 2.336 | 0.126 |
Resection margins(R0/R1) | 58(90.6%)/6(9.4%) | Â | 76(79.2%)/20(20.8%) | 3.705 | 0.054 |